Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human IL-17A&IL-17F Heterodimer Protein, His Tag&Strep II Tag, 100 µg  

Recombinant Human IL-17A&IL-17F Heterodimer Protein, His Tag&Strep II Tag, 100 µg

Recombinant Human IL-17A&IL-17F Heterodimer Protein, expressed from human HEK293 cells,  contains AA Gly 24 - Ala 155 (IL-17A) & Arg 31 - Gln 163 (IL-17F), His Tag&Strep II Tag

Synonym
recombinant, human, protein, IL-17A, Interleukin-17A, CTLA-8, IL-17, IL-17F, IL24, ML-1, Interleukin-17F

More details

ILF-H52WF-100

Availability: within 7 days

605,00 €

Background
Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

Source
Recombinant Human IL-17A&IL-17F Heterodimer Protein, His Tag&Strep II Tag (ILF-H52WF) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Ala 155 (IL-17A) & Arg 31 - Gln 163 (IL-17F) (Accession # Q16552-1 (IL-17A) & Q96PD4-1 (IL-17F)). Two sequential affinity purification steps were used to ensure exact 1:1 molar ratio of IL17A&IL17F heterodimer.
Predicted N-terminus: His (IL-17A) & Ser (IL-17F)

Molecular Characterization
Human IL-17A&IL-17F Heterodimer Protein, His Tag&Strep II Tag, produced by co-expression of IL-17A and IL-17F, has a calculated MW of 17.0 kDa (IL-17A) and 18.4 kDa (IL-17F). Subunit IL-17A is fused with a polyhistidine tag at the N-terminus and subunit IL-17F is fused with a Twin Strep tag at the N-terminus. The reducing (R) protein migrates as 19 kDa (IL-17A) and 21 kDa (IL-17F) respectively due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.
 
Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution. 

Bioactivity-ELISA
Immobilized Human IL-17A&IL-17F Heterodimer Protein, His Tag&Strep II Tag (Cat. No. ILF-H52WF) at 2 μg/mL (100 μL/well) can bind Human IL-17 RA, Fc Tag (Cat. No. ILA-H5257) with a linear range of 0.039-0.625 μg/mL (QC tested).
Immobilized Anti-IL17A MAb, Human IgG1 at 2 μg/mL (100 μL/well) can bind Human IL-17A&IL-17F Heterodimer Protein, His Tag&Strep II Tag (Cat. No. ILF-H52WF) with a linear range of 0.2-3 ng/mL (Routinely tested).

References

(1)  Yao Z., et al.,1995, J. Immunol. 155:5483-5486.
(2)  Gerhardt S., et al., 2009, J. Mol. Biol. 394:905-921.